Ainara Elorza
Research Subjects
Research Interests
Ainara Elorza has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Jose Javier Lucas
Centro de Biología Molecular Severo Ochoa (CBM), CSIC – Universidad Autónoma de Madrid, Madrid, Spain
3 shared publications - María Santos-Galindo
Instituto Cajal, C.S.I.C., Madrid, Spain
3 shared publications - Alberto Parras
VivoArchitect Sàrl, Route de la Corniche 5A, 1066 Epalinges, Swizertland
2 shared publications - David Lozano-Muñoz
Centro de Biologia Molecular 'Severo Ochoa' (CBM) CSIC/UAM
2 shared publications Belén Pérez
Center for Molecular Biology “Severo Ochoa” (CBMSO) CSIC/UAM, Madrid, 28049, Spain
1 shared publication- Daniel Macías-García
Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, 41013, Spain
1 shared publication
Latest Publications
- Open Access
Correction of RBFOX1 deficit rescues Huntington’s disease mis-splicing and pathology
RNA mis-splicing correction therapies have been developed for neurological disorders like spinal muscular atrophy and neuronal ceroid lipofuscinosis. In Huntington’s disease (HD), pathogenic mis-splicing was initially observed in genes linked to neurodegeneration, such as HTT itself, MAPT , and TAF1 . Later, genome-wide analyses identified a broader mis-splicing signature in HD brains, involving additional neurodegeneration-related genes. Correcting each mis-spliced gene individually would be unfeasible, highlighting the need to target upstream splicing factors altered in HD. Our previous motif-enrichment analyses of intronic sequences flanking the exons mis-spliced in HD identified RBFOX and U2AF2 as candidate splicing factors, both of which are reduced in HD brains. In this study, we tested their pathogenic relevance generating conditional transgenic mouse models that overexpress RBFOX1 or U2AF2 in forebrain neurons and combining them with HD mice. Our results show that moderate overexpression of RBFOX1, but not U2AF2, corrects multiple HD-associated mis-splicing events and alleviates HD mice neuropathology and motor symptoms. These findings demonstrate that RBFOX1 downregulation contributes to HD pathology and underscore the therapeutic potential of strategies aimed at increasing RBFOX1 levels.
Open AccessCorrection of RBFOX1 deficit rescues Huntington’s disease mis-splicing and pathology
RNA mis-splicing correction therapies have been developed for neurological disorders like spinal muscular atrophy and neuronal ceroid lipofuscinosis. In Huntington’s disease (HD), pathogenic mis-splicing was initially observed in genes linked to neurodegeneration, such as HTT itself, MAPT , and TAF1 . Later, genome-wide analyses identified a broader mis-splicing signature in HD brains, involving additional neurodegeneration-related genes. Correcting each mis-spliced gene individually would be unfeasible, highlighting the need to target upstream splicing factors altered in HD. Our previous motif-enrichment analyses of intronic sequences flanking the exons mis-spliced in HD identified RBFOX and U2AF2 as candidate splicing factors, both of which are reduced in HD brains. In this study, we tested their pathogenic relevance generating conditional transgenic mouse models that overexpress RBFOX1 or U2AF2 in forebrain neurons and combining them with HD mice. Our results show that moderate overexpression of RBFOX1, but not U2AF2, corrects multiple HD-associated mis-splicing events and alleviates HD mice neuropathology and motor symptoms. These findings demonstrate that RBFOX1 downregulation contributes to HD pathology and underscore the therapeutic potential of strategies aimed at increasing RBFOX1 levels.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S443
IN VIVO INTERROGATION OF THE CONTRIBUTION OF SPECIFIC SPLICING FACTORS TO PATHOLOGICAL MIS-SPLICING IN HUNTINGTON´S DISEASE
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S443
Open AccessIN VIVO INTERROGATION OF THE CONTRIBUTION OF SPECIFIC SPLICING FACTORS TO PATHOLOGICAL MIS-SPLICING IN HUNTINGTON´S DISEASE
- 29 September 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (613) , eabe7104
CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington’s disease
Altered CPEBs and mRNA polyadenylation lead to thiamine deficiency in the brains of patients and mice with Huntington’s disease.
- 29 September 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (613) , eabe7104
CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington’s disease
Altered CPEBs and mRNA polyadenylation lead to thiamine deficiency in the brains of patients and mice with Huntington’s disease.